A Hub for Regulatory, Compliance, and Business Insights
The legal and regulatory landscape surrounding peptides continues to evolve rapidly, creating new compliance considerations, business opportunities, and potential risks for companies across the industry. From FDA policy and compounding requirements to enforcement activity, advertising, telehealth, litigation, and emerging business models, staying informed is critical for organizations operating in the peptide marketplace.
Frier Levitt’s Peptide Legal & Regulatory Resource Center brings together our latest insights on the issues shaping this evolving industry. Explore articles and legal updates, webinars and events, media coverage featuring Frier Levitt attorneys, and other resources designed to help peptide manufacturers, compounding pharmacies, telehealth platforms, healthcare providers, wellness businesses, investors, and other industry stakeholders stay informed about important legal, regulatory, and business developments.
Featured Articles
- Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook
– August 18, 2026
Eli Lilly and Company filed six federal lawsuits on August 12, 2026, against businesses it accuses of illegally selling retatrutide, the company’s experimental “triple-agonist” obesity drug that has not yet been approved by the U.S. FDA or any other regulator worldwide… - FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List – April 16, 2026
The U.S. Food and Drug Administration (FDA) has taken steps that may affect the legal status of popular compounded peptides under section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)… - The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry – March 10, 2026
The peptide compounding market is at an inflection point. Recent comments from U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. suggest that the regulatory window for properly licensed and compliant compounding pharmacies…
Featured Media Coverage
- Edgar Asebey Featured in CNN Health: “FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next” – July 31, 2026
The FDA’s review of several peptides continues to move forward following a closely watched vote by the Pharmacy Compounding Advisory Committee (PCAC), which recommended adding six peptides to the FDA’s 503A Bulks List. - Jesse Dresser and Edgar Asebey Featured in CNN Health: “The future of peptides in the US is about to become clearer. Here’s what you should know” – July 22, 2026
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is meeting this week to consider whether seven widely discussed peptides should be eligible for compounding by 503A pharmacies. This is a decision that could significantly impact compounding pharmacies, healthcare providers, telehealth companies, and the broader peptide industry. - Jesse Dresser Featured in Forbes: “Peptides May Soon Be Legal. These Companies Are Ready To Cash In” – July 22, 2026
The FDA’s review of seven peptides has sparked significant interest across the healthcare industry, with compounding pharmacies, telehealth companies, investors, and other market participants preparing for the possibility of expanded legal access to peptide compounding.
Featured Webinars
- The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models – August 20, 2026
Pharmacy compounding remains one of the most closely watched areas of FDA enforcement, particularly as compounded GLP-1s and peptides continue to draw regulatory and manufacturer attention… - FDA’s July Peptide Review: What the PCAC Meeting Means for Peptide Compounding – July 22, 2026
The peptide industry is approaching one of its most consequential regulatory moments in recent years. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) considers whether seven peptides should be added to the 503A Bulks List.… - Legal Insights into GLP-1 and Peptide Compounding in 2026 – March 18, 2026
As GLP-1 medications and peptide therapies continue to face heightened regulatory scrutiny, pharmacies and telehealth providers must navigate a rapidly shifting enforcement landscape…
Meet Our Team
Edgar J. Asebey
Partner
973-852-8392
easebey@frierlevitt.com
Jesse C. Dresser
Partner
973-852-8361
jdresser@frierlevitt.com
Guilherme Ferrari Faviero
Senior Associate
332-205-6585
gferrari@frierlevitt.com
Arielle T. Miliambro
Partner
973-852-8379
amiliambro@frierlevitt.com
Melissa Roy
Associate
862-210-2064
mroy@frierlevitt.com
Brandon S. Zarsky
Partner
973-852-8398
bzarsky@frierlevitt.com
